Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD

Expert Review of Respiratory Medicine

Volumn 4, Issue 6, 2010, Pages 703-714

  Tashkin, Donald P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

budesonide; chronic obstructive pulmonary disease; COPD; formoterol; pressurized metered dose inhaler

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; PLACEBO; PREDNISOLONE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BONE DENSITY; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; METERED DOSE INHALER; MORNING DOSAGE; PNEUMONIA; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SYMPTOM; THRUSH;

EID: 78650056959     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.77     Document Type: Article

References (46)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504 (1997).
2. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 4, 554-564 (2007).
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57, 847-852 (2002).
4. Stevenson NJ, Walker PP, Costello RW et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 172, 1510-1516 (2005).
5. Spencer S, Jones PW; GLOBE study group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 58, 589-593 (2003).
6. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60, 925-993 (2005).
7. Cooper CB, Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. Br. Med. J. 330, 640-644 (2005).
8. Sin DD, Finlay A, McAlister SF et al. Contemporary management of chronic obstructive pulmonary disease: Scientifc Review. JAMA 290, 2301-2312 (2003).
9. Jenkins CR, Gones PW, Calverley PM et al. Effcacy of salmeterol/ futicasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH study. Respir. Res. 10, 59 (2009).
10. Nelson HS, Weiss ST, Bleecker ER et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129, 15-26 (2006).
11. Mann M, Chowdhury B, Sullivan E et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 124, 70-74 (2003).
12. Donnelly R, Seale JP. Clinical pharmacokinetics of inhaled budesonide. Clin. Pharmacokinet. 40, 427-440 (2001).
13. Zhang M, Fawcett JP, Shaw JP. Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. Br. J. Clin. Pharmacol. 54, 246-250 (2002).
14. Szafranski W, Cukier A, Ramirez A et al. Effcacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 21, 74-81 (2003).
15. Calverley PM, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 22, 912-919 (2003).
16. Eklund A, Tronde A, Jonannes-Hellberg I et al. Pharacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. Biopharm. Drug Dispos. 29, 382-395 (2008).
17. Tronde A, Gillen M, Borgstrom L et al. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J. Clin. Pharacol. 48, 1300-1308 (2008).
18. Chambers F, Ludzik A. In vitro drug delivery performance of a new budesonide/formoterol pressurinzed metered-dose inhaler. J. Aerosol Me d. Pulm. Drug Deliv. 22, 113-120 (2009).
19. Miller CJ, Senn S, Mezzanotte WS. Bronchodilation of formoterol administered with budesonide: device and formulation effects. Contemp. Clin. Trials 29, 114-124 (2008).
20. Bousquet J, Huchon G, Leclerc V et al. A randomized, double-blind, double-dummy, single-dose, effcacy crosover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer™) and placebo (pMDI or Aerolizer™) in asthmatic patients. Respiration 72(Suppl. 1), 6-12 (2005).
21. Noonan M, Rosenwasser LJ, Martin P et al. Effcacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma. A randomized clinical trial. Drugs 66, 2235-2254 (2006).
22. Corren J, Korenblat PE, Miller CJ et al. Twelve-week, randomized, placebo-controlled, multicenter study of the effcacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin. Ther. 29, 823-843 (2007).
23. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting ß-agonists in the treatment of asthma. N. Engl. J. Med. 362, 1169-1171 (2010).
24. Tashkin DP, Rennard SI, Martin P et al. Effcacy and tolerability of budesonide and formoterol administered in one pressurized metered-dose inhaler over 6 months in patients with moderate to very severe chronic obstructive pulmonary disease. Drugs 68, 1975-2000 (2008).
25. Rennard SI, Tashkin DP, McElhattan J et al. One-year evaluation of the effcacy and tolerability of budesonide/formoterol in one hydrofuoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease. Drugs 69, 549-565 (2009).
26. Leidy NK, Schmier JK, Jones MKC et al. Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respir. Med. 97, S59-S70 (2003).
27. Jones PW, Quirk FH, Baveystock CM et al. A self-complete measure of health status for chronic airfow limitation. The St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 145, 1321-1327 (1992).
28. Shah S, White M, Uryniak T et al. The functionality of a budesonide/formoterol pressurized metered-dose inhaler with an integrated actuation counter. Allergy Asthma Proc. 31, 40-48 (2010).
29. Melani AS, Zanchetta Z, Sestini N et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann. Allergy Asthma Immunol. 93, 439-446 (2004).
30. Calverley PM, Anderson JA, Celli B et al. Salmeterol and futicasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775-789 (2007).
31. Wedzicha JA, Calverley PM, Seemungal TA et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/futicasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 177, 19-26 (2008).
32. Ernst P, Gonzalez AV, Brassard P et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am. J. Respir. Crit. Care Med. 176, 162-166 (2007).
33. Drummond MB, Dasenbrook EC, Pitz M W et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300, 2407-2416 (2008).
34. Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of pneumonia: a pooled analysis of clinical trials. Lancet 374, 712-719 (2008).
35. Esmailpour N, Hogger P, Rohdewald P. Binding of glucocorticoids to human nasal tissue in vitro. Int. Arch. Allergy Immunol. 122, 151-154 (2000).
36. Mortimer KJ, Tattersfeld AE, Tang Y et al. Plasma concentrations of futicasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br. J. Clin. Pharmacol. 64, 439-444 (2007).
37. Welte T, Miravitlles M, Hernandez P et al. Effcacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180, 741-750 (2009).
38. Dahl R, Fan Chung K, Buhl R et al. Effcacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax 65, 473-479 (2010).
39. Fitzgerald MR, Fox JC. Emerging trends in the therapy of COPD: bronchodilators as mono-and combination therapies. Drug Discov. Today 12, 472-478 (2007).
40. ® Inhaler and pressurized metered dose inhalers. J. Aerosol Med. 18, 273-282 (2005).
41. Bateman E, Tashkin D, Siafakas N et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir. Med. 104(10), 1460-1472 (2010).
42. Nathan RA, Nolte H, Pearlman DS et al. Twenty-six week effcacy and safety study of mometasone furoate/formoterol 200/10 μ g combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 31, 269-279 (2010).
43. Weinstein SF, Corren J, Murphy K et al. Twelve-week effcacy and safety study of mometasone furoate/formoterol 200/10 and 400/10 μ g combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc. 31, 280-289 (2010).
44. Seifart C, Vogelmeier C. Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg. Drugs 14, 181-194 (2009).
45. Calverley PM, Rabe KF, Godhring UM et al. Rofumilast in moderate-to-severe chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 374, 685-694 (2009).
46. Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al. Rofumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. Lancet 374, 695-703 (2009).